» Articles » PMID: 37624589

Temporal Trends of Cause-specific Mortality After Diagnosis of Atrial Fibrillation

Overview
Journal Eur Heart J
Date 2023 Aug 25
PMID 37624589
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: Reports of outcomes after atrial fibrillation (AF) diagnosis are conflicting. The aim of this study was to investigate mortality and hospitalization rates following AF diagnosis over time, by cause and by patient features.

Methods: Individuals aged ≥16 years with a first diagnosis of AF were identified from the UK Clinical Practice Research Datalink-GOLD dataset from 1 January 2001, to 31 December 2017. The primary outcomes were all-cause and cause-specific mortality and hospitalization at 1 year following diagnosis. Poisson regression was used to calculate rate ratios (RRs) for mortality and incidence RRs (IRRs) for hospitalization and 95% confidence intervals (CIs) comparing 2001/02 and 2016/17, adjusted for age, sex, region, socio-economic status, and 18 major comorbidities.

Results: Of 72 412 participants, mean (standard deviation) age was 75.6 (12.4) years, and 44 762 (61.8%) had ≥3 comorbidities. All-cause mortality declined (RR 2016/17 vs. 2001/02 0.72; 95% CI 0.65-0.80), with large declines for cardiovascular (RR 0.46; 95% CI 0.37-0.58) and cerebrovascular mortality (RR 0.41; 95% CI 0.29-0.60) but not for non-cardio/cerebrovascular causes of death (RR 0.91; 95% CI 0.80-1.04). In 2016/17, deaths caused from dementia (67, 8.0%), outstripped deaths from acute myocardial infarction, heart failure, and acute stroke combined (56, 6.7%, P < .001). Overall hospitalization rates increased (IRR 2016/17 vs. 2001/02 1.17; 95% CI, 1.13-1.22), especially for non-cardio/cerebrovascular causes (IRR 1.42; 95% CI 1.39-1.45). Older, more deprived, and hospital-diagnosed AF patients experienced higher event rates.

Conclusions: After AF diagnosis, cardio/cerebrovascular mortality and hospitalization has declined, whilst hospitalization for non-cardio/cerebrovascular disease has increased.

Citing Articles

Identification and Functional Investigation of as a Novel Gene Underpinning Familial Atrial Fibrillation.

Jiang W, Sun Y, Qiu X, Wu S, Ding Y, Li N Diagnostics (Basel). 2024; 14(21).

PMID: 39518344 PMC: 11544904. DOI: 10.3390/diagnostics14212376.


Temporal trends in mortality and causes of death in patients with incident atrial fibrillation: a nationwide register study from 2010 to 2018.

Kouki E, Salmela B, Aro A, Halminen O, Teppo K, Haukka J BMJ Open. 2024; 14(9):e080836.

PMID: 39277207 PMC: 11407195. DOI: 10.1136/bmjopen-2023-080836.


Social drivers in atrial fibrillation occurrence, screening, treatment, and outcomes: systematic-narrative hybrid review.

Frost L, Johnsen S, Benjamin E, Trinquart L, Vinter N Eur Heart J Suppl. 2024; 26(Suppl 4):iv50-iv60.

PMID: 39099579 PMC: 11292415. DOI: 10.1093/eurheartjsupp/suae073.


Anticoagulation in patients with atrial fibrillation and chronic kidney disease: clinical complexity beyond thromboembolism.

Buoninfante G, Basili S, Romiti G Intern Emerg Med. 2024; 19(7):1797-1799.

PMID: 39096349 DOI: 10.1007/s11739-024-03733-1.


Global burden of atrial fibrillation/atrial flutter and its attributable risk factors from 1990 to 2021.

Cheng S, He J, Han Y, Han S, Li P, Liao H Europace. 2024; 26(7).

PMID: 38984719 PMC: 11287210. DOI: 10.1093/europace/euae195.


References
1.
Austin P, Lee D, Fine J . Introduction to the Analysis of Survival Data in the Presence of Competing Risks. Circulation. 2016; 133(6):601-9. PMC: 4741409. DOI: 10.1161/CIRCULATIONAHA.115.017719. View

2.
Cowan C, Healicon R, Robson I, Long W, Barrett J, Fay M . The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart. 2013; 99(16):1166-72. PMC: 3717828. DOI: 10.1136/heartjnl-2012-303472. View

3.
Smolina K, Wright F, Rayner M, Goldacre M . Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ. 2012; 344:d8059. PMC: 3266430. DOI: 10.1136/bmj.d8059. View

4.
Lawson C, Zaccardi F, Squire I, Ling S, Davies M, Lam C . 20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. Lancet Public Health. 2019; 4(8):e406-e420. PMC: 6686076. DOI: 10.1016/S2468-2667(19)30108-2. View

5.
Chua W . Clearing the cognitive cloud: direct oral anticoagulants or vitamin K antagonists for reducing dementia risk in patients with atrial fibrillation?. Heart. 2021; 107(23):1854-1855. DOI: 10.1136/heartjnl-2021-320138. View